Diabetic retinopathy can lead to peripheral or nighttime vision loss, visual disturbances, and, if left untreated, blindness.

Andrew Hade was diagnosed with diabetes a year ago. While the Rockford, Illinois, resident was surprised, he was more shocked ...

Treating diabetic retinopathy (DR) is still a significant challenge for clinicians and remains a leading cause of blindness worldwide. NovaGo Therapeutics is developing a human antibody therapy ...

Opens in a new tab or window Use of empagliflozin (Jardiance) was not linked to a lower risk of incident nonproliferative diabetic retinopathy compared with dipeptidyl peptidase-4 (DPP-4 ...

Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, did not reduce the risk for incident nonproliferative diabetic retinopathy compared with dipeptidyl peptidase 4 (DPP-4 ...

Empagliflozin initiation is not associated with incident nonproliferative diabetic retinopathy (NPDR) compared with ...

Investigators conducted a retrospective clinical audit to determine why patients do not adhere to the guidelines among about 9,000 patients in a practice.

An investigation led by Brigham and Women's Hospital finds empagliflozin (sold as Jardiance) may reduce the risk of diabetic retinopathy (DR) progression in patients with a history of ...

The pilot program will use non-mydriatic fundus cameras and artificial intelligence - developed by Ainnova Tech - to automatically analyze retinal images and identify microscopic changes in the retina ...

Diabetic retinopathy involves the changes for the blood vessels in your eye due to the high sugars that are in your body from diabetes, if you're a diabetic and you notice changes to your vision ...